IDEXX Laboratories stock holds firm on recurring diagnostics demand

IDEXX Laboratories (US45168D1046) stock is anchored by a business that generated $3.9 billion in fiscal 2025 revenue and a 31.0% operating margin, while the company also reported a 14% increase in companion animal diagnostic recurring revenue in the same period. Those figures frame the shares as a profitability story as much as a growth story.

Fiscal 2025 margin stayed high

IDEXX said fiscal 2025 revenue reached $3.9 billion, compared with $3.6 billion in fiscal 2024, and operating margin held at 31.0% versus 30.6% a year earlier. Net income for fiscal 2025 was $860 million, up from $770 million in fiscal 2024, according to the company’s annual reporting context on IDEXX Laboratories investor relations.

The number that stands out for investors is the combination of scale and margin: revenue rose by roughly $300 million year over year, while operating margin still stayed above 30%. That mix is what makes the stock sensitive to both growth in clinic testing and any change in pricing or utilization.

Recurring tests drive the model

Companion animal diagnostic recurring revenue increased 14% in fiscal 2025, showing that the installed base still feeds repeat demand. IDEXX also said net income rose by $90 million year over year, which points to operating leverage rather than simple top-line expansion.

For a diagnostics company, that matters more than a single-quarter headline. The company’s model depends on recurring consumables, testing volumes, and the ability to keep margins near the levels it delivered in 2025.

Revenue up 8.3%

IDEXX Laboratories stock fits a market that tends to reward consistency, and the latest annual numbers show why. Revenue moved from $3.6 billion in fiscal 2024 to $3.9 billion in fiscal 2025, an increase of about 8.3%, while operating margin improved by 0.4 percentage points.

That comparison is important because it shows the company did not trade profitability for growth. Instead, it expanded both revenue and net income in the same fiscal year, a combination that often supports valuation resilience in healthcare services names.

Product range still matters

The company’s core offering remains veterinary diagnostics, including instruments, consumables, and reference laboratory services. In practice, the business is built around recurring test demand rather than a one-time product cycle, which is why the 14% rise in recurring diagnostic revenue matters alongside the broader fiscal 2025 revenue base.

That structure also helps explain why the annual margin remains a key metric. When a company keeps operating margin at 31.0% while expanding revenue, the market usually focuses less on the product catalog and more on execution and clinic-level demand.

Valuation follows the margin

On the market side, the article does not rely on a live quote, so the more durable anchor is the fiscal 2025 revenue of $3.9 billion and net income of $860 million, both dated and evidenced in the company reporting context. Those numbers are the clearest current reference points for assessing the shares on a fundamental basis.

For IDEXX Laboratories stock, the central question is whether the company can keep converting recurring diagnostics demand into growth while defending a margin that remained above 30% in fiscal 2025.

Veterinary diagnostics stays central

IDEXX Laboratories still earns its strongest investor interest from veterinary diagnostics, where recurring tests and consumables support repeat revenue. The fiscal 2025 figures show that this core franchise produced $3.9 billion in revenue and $860 million in net income, which keeps the business firmly in the quality-growth camp.

That is the product story behind the stock: not a single launch cycle, but a recurring-services model with a 14% gain in companion animal diagnostic recurring revenue in fiscal 2025.

Shares on Nasdaq

IDEXX Laboratories stock trades on Nasdaq under IDXX, and the latest available evidence in this article is the company’s fiscal 2025 reporting base rather than a live market print. The shares are best read against the $3.9 billion revenue figure, the 31.0% operating margin, and the $860 million net income line from fiscal 2025.